Middle cerebral artery lesions mostly affect the dominant hemisphere i.e. the left cerebral hemisphere. Signs and Symptoms
Hemiparesis or hemiplegia of the lower half of the contralateral face
Hemiparesis or hemiplegia of the contralateral upper and lower extremities*
Sensory loss of the contralateral face, arm and leg*
Ataxia of contralateral extremities*
Speech impairments/aphasia: Brocas area, Wernickes or Global aphasia as a result of a dominant hemisphere lesion (usually the left brain)
Perceptual deficits: hemispatial neglect, anosognosia, apraxia, and spatial disorganization as a result of a non-dominant hemisphere lesion (usually the right brain)
Visual disorders: déviation conjuguée, a gaze preference towards the side of the lesion; contralateral homonymous hemianopsiaNote: *faciobrachial deficits greater than that of the lower limb

Diagnosis
Diagnosis can be confirmed by CT Scan or MRI for advanced investigations. References


== External links ==
Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching. It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City. Preparations containing it were first marketed under the name Synalar. A typical dosage strength used in dermatology is 0.01–0.025%. One such cream is sold under the brand name Flucort-N and includes the antibiotic neomycin. Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.Fluocinolone acetonide intravitreal implants have been used to treat non-infectious uveitis. A systematic review could not determine whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis. A fluocinolone acetonide intravitreal implant with the brand name Iluvien is sold by biopharmaceutical company Alimera Sciences to treat diabetic macular edema (DME).It was approved for medical use in 1961. Classification
Fluocinolone is a group V (0.025%) or group VI (0.01%) corticosteroid under US classification. See also
Topical steroid
Fluocinonide
Ciprocinonide
Glucocorticoid

References
External links
"Fluocinolone acetonide". Drug Information Portal. U.S. National Library of Medicine.